ProteoFormiX – a biomedical company that employs and develops innovative know-how to discover and identify disease biomarkers derived from short secretory proteins – is pleased to announce that it has been awarded a € 265K Research Grant by Flanders Innovation & Entrepreneurship (VLAIO).
The grant is destined to provide the biomedical company with clinical proof-of-concept of its proprietary technology. ProteoFormiX so aims to aid the development of early diagnostics and novel therapeutics for difficult-to-diagnose and presently incurable cancers and neurodegenerative diseases like Alzheimer's.
Founder and CSO Peter Verhaert states: "I am very excited that with this support of VLAIO, ProteoFormiX is officially entering its next chapter as a company. The following months we will finalize our analytical set-up and expand our scientific team. I very much look forward to focusing on the science again, effectively demonstrating how mass spectrometry histochemistry will be able to realize breakthroughs in the clinic."
ProteoFormiX currently has a job opening for a senior research position (postdoc level). Applications are open – read more on the post at proteoformix.com/jobs.